SKYLINEDX ANNOUNCES UPCOMING ORAL PRESENTATION AT THE 21ST INTERNATIONAL CONGRESS OF THE SOCIETY FOR MELANOMA RESEARCH
SKYLINEDX ANNOUNCES UPCOMING ORAL PRESENTATION AT THE 21ST INTERNATIONAL CONGRESS OF THE SOCIETY FOR MELANOMA RESEARCH
ROTTERDAM, Netherlands and SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announces that late-breaking data evaluating its Merlin test will be presented as part of the Plenary Session and a poster presentation at the upcoming Society for Melanoma Research (SMR) being held from October 10-13, 2024, in New Orleans, LA.
荷蘭鹿特丹和美國聖地亞哥，2024年10月8日 /PRNewswire/ -- SkylineDx，一家專注於腫瘤學、炎症和傳染病分子診斷研究與開發的創新診斷公司，宣佈將在即將舉行的美國新奧爾良舉辦的2024年10月10-13日舉行的黑色素瘤研究學會（SMR）的全體大會和海報展示中發佈評估其Merlin測試的最新數據。
|
The oral presentation will be part of Plenary Session 10: Late Breaking Clinical Abstracts | |
|
Oral |
"Prospective Multicenter Evaluation (MERLIN_001 Trial) of Clinicopathologic and Gene |
|
Expression Profile Test to Predict Sentinel Node Status in T1-T3 cNO Melanoma |
|
|
Date |
Sunday, October 13 |
|
Time |
10:45 AM CDT |
|
Presenter |
Vernon K. Sondak, MD, Department Chair, Cutaneous Oncology, Moffitt Cancer Center |
|
Poster Presentation Details | |
|
Poster |
CP-GEP Identifies T1a Melanoma Patients at Risk of Sentinel Lymph Node Metastasis |
|
Date |
Friday, October 11 |
|
Time |
1:00 – 2:00 PM CDT |
|
Presenter |
Alex Meves, MD, MBA, Dermatologist, Mayo Clinic |
|
口頭報告將作爲全體會議10：Late Breaking Clinical Abstracts的一部分。 | |
|
口頭 |
“前瞻性多中心評估（MERLIN_001試驗）臨床病理學和基因表達譜測試，用於預測T1-T3 cNO黑色素瘤哨兵淋巴結狀況 |
|
內 |
|
|
日期 |
星期日，十月十三日 |
|
Right Time |
上午十點四十五分 中部夏令時間 |
|
|
Vernon k. Sondak, MD, Cutaneous Oncology Department Chair, Moffitt Cancer Center |
|
海報展示詳細信息 | |
|
海報 |
CP-GEP識別患有T1a黑色素瘤的患者，可能存在哨兵淋巴結轉移的風險 |
|
日期 |
10月11日星期五 |
|
Right Time |
中部時間下午1點至下午2點 |
|
主持人 |
亞歷克斯·梅維斯，MD，MBA，梅奧診療皮膚科專家 |
About CP-GEP (Merlin test)
CP-GEP is a non-invasive prediction model for cutaneous melanoma patients that combines clinicopathologic (CP) variables with gene expression profiling (GEP). This model is able to identify cutaneous melanoma patients at low-risk for nodal metastasis who may forgo the sentinel lymph node biopsy (SLNB) procedure. The CP-GEP model was developed by Mayo Clinic and SkylineDx BV and it has been clinically validated in multiple studies. More information (including references) may be obtained at www.falconprogram.com and merlinmelanomatest.com. The test has been launched in the United States and Europe as Merlin test. SkylineDx collaborates with diagnostic service providers globally to bring this test to market and increase patient access. In the United States, Tempus is commercializing Tempus Merlin test. Quest Diagnostics launched their own LDT version of the CP-GEP model in the United States under the brand name MelaNodal Predict.
關於CP-GEP（Merlin測試）
CP-GEP是一個非侵入性的預測模型，用於結合臨床病理（CP）變量和基因表達譜（GEP）的黑色素瘤患者。該模型能夠識別低風險淋巴結轉移的黑色素瘤患者，可能可以避免前哨淋巴結活檢（SLNB）程序。CP-GEP模型由Mayo Clinic和SkylineDx BV開發，已在多項研究中進行了臨床驗證。可在www.falconprogram.com和merlinmelanomatest.com獲取更多信息（包括參考文獻）。該測試已在美國和歐洲推出，稱爲梅林測試。SkylineDx與全球診斷服務提供商合作，將該測試引入市場並提高患者可及性。在美國，Tempus正在商業化Tempus Merlin測試。奎斯特診療在美國推出了他們自己的LDt版本的CP-GEP模型，品牌名爲MelaNodal Predict。
About SkylineDx
SkylineDx is a biotechnology company focused on research & development of molecular diagnostics in oncology inflammatory, and infectious diseases. SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predicting a patient's response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient. SkylineDx is headquartered in Rotterdam. the Netherlands, complemented by a U.S. base of operations and a CAP/CLIA certified laboratory in San Diego California, USA. To learn more about SkylineDx, please visit .
關於SkylineDx
SkylineDx是一家專注於腫瘤炎症和傳染病分子診斷研究與開發的生物技術公司。SkylineDx利用其專業知識彌合了學術發現的基因表達特徵與具有高臨床效用的商業化診斷產品之間的差距，幫助醫療服務專業人員準確判斷疾病類型或狀態，預測患者對治療的反應。基於測試結果，醫療服務專業人員可以針對個體患者定製治療方案。SkylineDx總部位於荷蘭鹿特丹，輔之以美國運營基地和位於美國加利福尼亞州聖迭戈的CAP/CLIA認證實驗室。要了解更多關於SkylineDx，請訪問。
SOURCE SkylineDx
來源：SkylineDx
